The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.

The Dividend Kings underperformed in 2024. Read here to know about the top 18 most opportune Dividend Kings based on ...

In the chart below, we zoom in on the different ownership groups of AbbVie. Institutions typically ... On studying our ownership data, we found that 25 of the top shareholders collectively own ...

This data can help you track the liquidity and interest for AbbVie's options for a given ... 20-year pro options trader reveals his one-line chart technique that shows when to buy and sell.

In last week’s Sunday Digest, I (Tom Yeung) wrote how cyclical companies are often incredible investments. Firms like copper ...

AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

Looking ahead, Guggenheim highlighted several potential catalysts for AbbVie, including Phase 2 data for ABBV-552, a small molecule SV2A modulator in Alzheimer's Disease, expected early in 2025.

Understanding potential pitfalls—and how to overcome them—can help organizations maximize the value of this technology.